Immune Checkpoint Inhibitors in Gastrointestinal Cancers: Current Evidence and Future Directions

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Cancer immunotherapy, particularly Immune Checkpoint Inhibitors (ICIs), is a vital treatment for various cancers.
• ICIs have demonstrated efficacy in gastrointestinal cancers like esophageal, gastric, and colorectal cancer.
• Optimal timing and integration of ICIs into treatment strategies differ across gastrointestinal cancer types.

Purpose of the Study:

• To review current evidence on ICI-based treatments for gastrointestinal cancers.
• To provide an overview of ongoing and emerging treatment strategies involving ICIs.
• To discuss the role of conversion surgery in conjunction with ICI therapy for gastrointestinal cancers.

Main Methods:

• Systematic review of clinical trials and basic research on ICIs in gastrointestinal cancers.
• Analysis of treatment strategies, including ICI timing and combination therapies.
• Evaluation of the role of conversion surgery as a local control method.

Main Results:

• ICI efficacy varies by gastrointestinal cancer type, necessitating tailored treatment approaches.
• Ongoing clinical trials and research are continuously refining ICI treatment paradigms.
• Conversion surgery is emerging as a key option for local control in multidisciplinary ICI-based treatment plans.

Conclusions:

• ICI-based treatments are evolving, offering new systemic control options for gastrointestinal cancers.
• Integrating ICIs with conversion surgery presents a promising multidisciplinary approach for managing difficult-to-control lesions.
• Future strategies will likely involve personalized ICI selection and timely surgical intervention for improved patient outcomes.